Aktienanalyse zu Revelation Biosciences Inc (REVB)REVBRevelation Biosciences Inc

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Revelation Biosciences Inc is currently not a strong buy due to its ongoing financial losses and recent stock performance. The current price is $3.69, which is significantly down 83.77% year-to-date and 87.31% over the past year. Although the company has a potential total addressable market of $94 billion for its product Gemini, the recent earnings report showed a GAAP EPS of -5.92, indicating continued challenges in profitability. The main risk is the company's high net loss of $59.76 million for FY 2025, which raises concerns about its financial sustainability.

1 analysts cover REVB: 1 rate it Buy, 0 Hold and 0 Sell.